Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
Journal Title: Journal of Vaccines & Immunization - Year 2015, Vol 3, Issue 2
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardiovascular disease, pulmonary disease, or diabetes mellitus). This analysis is consistent with data suggesting immunocompetent at-risk populations aged ≥50 years produce functional anti-pneumococcal antibody responses to PCV13 comparable to those not at risk. An OPA titer that correlates with protection has not been defined for adults; however, PCV13 elicits generally higher responses than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) one month after vaccination. PCV13 vaccination of immunocompetent at-risk populations likely results in benefits analogous to those without additional risk.
Authors and Affiliations
Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Sundaraiyer V, Gruber WC, Scott DA, Isturiz RE
Keywords
Related Articles
- EP ID EP566654
- DOI 10.14312/2053-1273.2015-2
- Views 49
- Downloads 0
Events following BCG vaccination during neonatal period and factors that might affect potency and side effects
Introduction: In Sri Lanka, BCG vaccine is given during neonatal period. There are many myths regarding BCG vaccine and sequelae of vaccination are not clearly documented in medical literature. Objectives: Objectives of...
Comparison of the live attenuated mumps vaccine (Miyahara strain) with its preattenuated parental strain
Live attenuated mumps vaccines have been developed by passaging the field isolates in cells that differ from the natural host. To study mumps viral (MuV) attenuation at the genomic level, we compared a live attenuated mu...
Routine immunization services in Africa: back to basics
National immunization programmes were created as a sequel to smallpox eradication when countries undertook mass immunization campaigns and other control measures to fight the disease. As smallpox came near to eradication...
An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary...
Silk-based microneedle transdermal immunization with EV71 vaccines elicits potent immune responses in mice
Hand, foot, and mouth disease (HFMD), caused by EV71 viral infection, has emerged as a serious public health concern in the Asia-Pacific region. The lack of effective treatment has led to a focus on controlling EV71 epid...